Cargando…

Rivaroxaban compared with low-dose aspirin in individuals with type 2 diabetes and high cardiovascular risk: a randomised trial to assess effects on endothelial function, platelet activation and vascular biomarkers

AIMS/HYPOTHESIS: Individuals with type 2 diabetes mellitus and subclinical inflammation have stimulated coagulation, activated platelets and endothelial dysfunction. Recent studies with the direct factor Xa inhibitor rivaroxaban in combination with low-dose aspirin demonstrated a significant reducti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pistrosch, Frank, Matschke, Jan B., Schipp, Dorothea, Schipp, Bernhard, Henkel, Elena, Weigmann, Ingo, Sradnick, Jan, Bornstein, Stefan R., Birkenfeld, Andreas L., Hanefeld, Markolf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563606/ https://www.ncbi.nlm.nih.gov/pubmed/34495376 http://dx.doi.org/10.1007/s00125-021-05562-9

Ejemplares similares

The metabolic vascular syndrome - guide to an individualized treatment
por: Hanefeld, Markolf, et al.
Publicado: (2016)

Intra-individual variability and circadian rhythm of vascular endothelial growth factors in subjects with normal glucose tolerance and type 2 diabetes
por: Hanefeld, Markolf, et al.
Publicado: (2017)

Shifting the Disease Management Paradigm From Glucose: What are the cons?
por: Hanefeld, Markolf, et al.
Publicado: (2009)

Is Hyperglycemia a Cardiovascular Risk Factor?
por: Pistrosch, Frank, et al.
Publicado: (2011)

Vascular protective effect of aspirin and rivaroxaban upon endothelial denudation of the mouse carotid artery
por: Mastenbroek, T. G., et al.
Publicado: (2020)

Deploying secure containers for training and development
por: Schipp, Jon, et al.
Publicado: (2016)

Low-dose aspirin and rivaroxaban combination therapy to overcome aspirin non-sensitivity in patients with vascular disease
por: Khan, Hamzah, et al.
Publicado: (2022)

Intravenous Ferric Carboxymaltose in Patients with Type 2 Diabetes Mellitus and Iron Deficiency: CLEVER Trial Study Design and Protocol
por: Schindler, Christoph, et al.
Publicado: (2017)

Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes
por: Hanefeld, Markolf
Publicado: (2007)

Biomarker monitoring of controlled dietary acrylamide exposure indicates consistent human endogenous background
por: Goempel, Katharina, et al.
Publicado: (2017)

Sudomotor Testing of Diabetes Polyneuropathy
por: Krieger, Sarah-Maria, et al.
Publicado: (2018)

Differential Inhibition of Platelet Reactivity by Dual Therapy With Aspirin and Low-Dose Rivaroxaban in Peripheral Arterial Disease: A Pilot Study
por: Jurk, Kerstin, et al.
Publicado: (2022)

Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
por: Eikelboom, John W, et al.
Publicado: (2022)

Insulin Use Early in the Course of Type 2 Diabetes Mellitus: The ORIGIN Trial
por: Hanefeld, Markolf, et al.
Publicado: (2013)

The Current and Potential Therapeutic Use of Metformin—The Good Old Drug
por: Drzewoski, Józef, et al.
Publicado: (2021)

Rivaroxaban with Aspirin Versus Aspirin for Peripheral Arterial Disease and Intermittent Claudication. Rationale and Design of the COMPASS CLAUDICATION Trial
por: Ramacciotti, Eduardo, et al.
Publicado: (2022)

Rivaroxaban and Aspirin in Peripheral Vascular Disease: a Review of Implementation Strategies and Management of Common Clinical Scenarios
por: McClure, Graham R., et al.
Publicado: (2019)

Mitochondrial mitophagy protection combining rivaroxaban and aspirin in high glucose-exposed human coronary artery endothelial cell. An in vitro study
por: Zekri-Nechar, Khaoula, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in Patients with Coronary and Peripheral Artery Diseases in Italy
por: Ferrara, Pietro, et al.
Publicado: (2021)

Heavy menstrual bleeding in women on anticoagulant treatment for venous thromboembolism: Comparison of high‐ and low‐dose rivaroxaban with aspirin
por: Boonyawat, Kochawan, et al.
Publicado: (2021)

Commentary: Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared With Aspirin Alone in Patients With Coronary and Peripheral Artery Diseases in Italy
por: Rawal, Shalin, et al.
Publicado: (2022)

Cardiac implications of hypoglycaemia in patients with diabetes – a systematic review
por: Hanefeld, Markolf, et al.
Publicado: (2013)

The Potential of Electrical Stimulation and Smart Textiles for Patients with Diabetes Mellitus
por: Engler, Babette, et al.
Publicado: (2022)

Venous thromboembolism prophylaxis after total knee arthroplasty (TKA): aspirin vs. rivaroxaban()
por: Colleoni, Jose Luiz, et al.
Publicado: (2017)

Impact of the individual components of the metabolic syndrome and their different combinations on the prevalence of atherosclerotic vascular disease in type 2 diabetes: the Diabetes in Germany (DIG) study
por: Hanefeld, Markolf, et al.
Publicado: (2007)

Platelets, Aspirin and Cardiovascular Disease
por: Elwood, P. C.
Publicado: (1976)

Fifty years with aspirin and platelets
por: Patrono, Carlo
Publicado: (2022)

Increased Levels of Platelets and Endothelial-Derived Microparticles in Patients With Non-Valvular Atrial Fibrillation During Rivaroxaban Therapy
por: Lenart-Migdalska, Aleksandra, et al.
Publicado: (2021)

Effects of insulin glargine versus metformin on glycemic variability, microvascular and beta-cell function in early type 2 diabetes
por: Pistrosch, F., et al.
Publicado: (2013)

A review of glucagon‐like peptide‐1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitus
por: Owens, David R., et al.
Publicado: (2017)

Bleeding Complication of Triple Therapy of Rivaroxaban, Prasugrel, and Aspirin: A Case Report and General Discussion
por: Gruenebaum, Dane D., et al.
Publicado: (2014)

Bleeding risks with novel oral anticoagulants especially rivaroxaban versus aspirin: a meta-analysis
por: Chen, Xiehui, et al.
Publicado: (2021)

Fatal adverse events of rivaroxaban combined with aspirin: an analysis using data from VigiBase
por: Zhang, Qingxia, et al.
Publicado: (2022)

Effects of Rivaroxaban on Platelet Activation and Platelet–Coagulation Pathway Interaction: In Vitro and In Vivo Studies
por: Perzborn, Elisabeth, et al.
Publicado: (2015)

Remission of type 2 diabetes and pleiotropic effects of long-term testosterone treatment for “late-onset” hypogonadism: A case report
por: Haider, Ahmad, et al.
Publicado: (2019)

The use of lipid-lowering therapy and effects of antihyperglycaemic therapy on lipids in subjects with type 2 diabetes with or without cardiovascular disease: a pooled analysis of data from eleven randomized trials with insulin glargine 100 U/mL
por: Hanefeld, Markolf, et al.
Publicado: (2017)

Early Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: Lessons from ORIGIN and Other Cardiovascular Trials
por: Hanefeld, Markolf, et al.
Publicado: (2016)

Rationale for Timely Insulin Therapy in Type 2 Diabetes Within the Framework of Individualised Treatment: 2020 Update
por: Hanefeld, Markolf, et al.
Publicado: (2020)

Immune Modulation to Enhance Bone Healing—A New Concept to Induce Bone Using Prostacyclin to Locally Modulate Immunity
por: Wendler, Sebastian, et al.
Publicado: (2019)

Measurement of Platelet Function in an Experimental Stroke Model With Aspirin and Clopidogrel Treatment
por: Lieschke, Franziska, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_obof5va2m6f594bgpu3lbec5m4